SGMO - サンガモ・セラピュ―ティクス (Sangamo Therapeutics Inc.) サンガモ・セラピュ―ティクス

 SGMOのチャート


 SGMOの企業情報

symbol SGMO
会社名 Sangamo Therapeutics Inc (サンガモ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サンガモ・セラピューティクス(Sangamo Therapeutics Inc)(旧名:Sangamo BioSciences Inc)は臨床病期のバイオ技術会社である。同社は化学を、ゲノム編集、遺伝子治療、遺伝子調節及び細胞治療にある同社のプラットフォーム技術を利用することによって患者の生活を変化させるゲノム療法への転換に従事する。同社は臨床開発・臨床前プログラムを開発していて、臨床開発・商業開発を促進するために、バイオ医薬品会社との特定のプログラムを提携させた。同社はヒトの治療法の開発を主とする。同社の製品ラインは、SB-525、SB-FIX、SB-318、SB-913、SB-728-TおよびSB-728-HSPCを含む。同社は血友病Bの治療のためのジンクフィンガーヌクレアーゼ(ZFN)インビボゲノム編集手法を評価する第I / II相臨床試験を開始した。ZFP技術プラットフォームの開発では、ヒト治療・非治療用途のための製品開発にそのリソースを集中している。  サンガモ・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。亜鉛フィンガ―デオキシリボ核酸(DNA)結合タンパク質(ZFP)などの自然発生タンパク質の研究により、遺伝子治療薬の開発・製品化に従事。後天性免疫不全症候群(エイズ)、血友病、ハンチントン病などの遺伝子治療薬を臨床・開発する。本社所在地はカリフォルニア州リッチモンド。   Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.
本社所在地 501 Canal Boulevard Richmond CA 94804 USA
代表者氏名 Alexander D. Macrae Alexander D. Macrae
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 510-970-6000
設立年月日 34851
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 182人
url https://www.sangamo.com/
nasdaq_url https://www.nasdaq.com/symbol/sgmo
adr_tso
EBITDA EBITDA(百万ドル) -64.84900
終値(lastsale) 14.23
時価総額(marketcap) 1446817562.11
時価総額 時価総額(百万ドル) 1412.249
売上高 売上高(百万ドル) 58.94200
企業価値(EV) 企業価値(EV)(百万ドル) 898.98300
当期純利益 当期純利益(百万ドル) -62.27200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sangamo Therapeutics Inc revenues increased from $11.7M to $34.1M. Net loss increased 26% to $36.8M. Revenues reflect Collaboration agreements increase from $11.3M to $33.8M. Higher net loss reflects Other Research and development increase of 92% to $48.9M (expense) Other General and administrative increase of 70% to $18.7M (expense).

 SGMOのテクニカル分析


 SGMOのニュース

   Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast  2021/07/29 20:30:00 Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarte
   Analysis of Global Gene Therapy Market Drivers and Challenges Report 2021 | Voyager Therapeutics, Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Human Stem Cells Institute PJSC  2021/07/29 12:13:15 OpenPR
Brief and concise information on Global gene therapy market has been published by Absolute Markets Insights. The report is especially designed to stimulate entrepreneurial sagacity. An overview of primary and secondary exploratory techniques are especially enlightening. Various economic attributes of
   Genome Editing Market Thriving Revenue of US$ 10,691.0 million by 2025 with Leading Vendors: Transposagen Biopharmaceuticals, Inc., Integrated DNA Technologies, Inc., GenScript, Horizon Discovery Group plc, Sangamo Therapeutics, Inc.  2021/06/11 06:10:22 OpenPR
The global genome editing market is expected to reach US$ 10,691.0 million by 2025 from US$ 3,210.1 million in 2017; it is estimated to grow at a CAGR of 17.0% from 2018 to 2027. Genome editing is a technique that is
   Global mRNA Vaccines & Therapeutics Market 2020 Key Drivers and Identified Segments Moderna Therapeutics, Tiba Biotechnology, CureVac, BioNTech, Sangamo Therapeutics  2021/06/09 13:24:20 Jumbo News
Global mRNA Vaccines & Therapeutics Market Growth 2020-2025 organized and published by MarketsandResearch.biz encloses comprehensive analysis on the market and are assessed through volume and value data. The report provides details about the market dynamics affecting the market, market scope, market segmentation and highlights the favorable competitive landscape and trends prevailing over the years. The []
   Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer Wire  2021/06/04 03:07:26 Business Wire
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer Business Wire
   BioMarin: Too Soon To Buy  2021/06/02 16:11:25 Seeking Alpha
   BioMarin: Depressed Price Due To CRL, Major Catalysts Ahead  2021/06/01 03:00:00 Seeking Alpha
   Global Hemophilia Gene Therapy Market by Share, Vendors, Growth Rate, Analysis, Product Type, Revenue | Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics  2021/03/05 12:03:29 OpenPR
Latest Research Study on Global Hemophilia Gene Therapy Market published by Research N Reports, offers a detailed overview of the factors influencing the global business scope. Hemophilia Gene Therapy Market research report shows the latest market insights with upcoming trends
   mRNA Vaccines & Therapeutics Market Swot Analysis by key players CureVac, Translate Bio, BioNTech, Sangamo Therapeutics  2021/03/03 10:20:57 OpenPR
Latest Market intelligence report released by HTF MI with title "Global mRNA Vaccines & Therapeutics Market Growth 2021-2026" is designed covering micro level of analysis by manufacturers and key business segments. The Global mRNA Vaccines & Therapeutics Market survey analysis
   Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results  2021/02/24 21:01:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlights. “We are very pleased with our execution and the progress we made in the challenging year of 2020 during the pandemic, where we advanced our hemophilia A product candidate into a Phase 3 clinical trial with Pfizer, dosed patients in our Phase 1/2 clinical study evaluating our wholly owned produ
   Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences  2021/02/18 21:15:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Cowen 41st Annual Health Care Conference Date: Monday, March 1st at 2:40 p.m. Eastern Time H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9th at 7:00 a.m. Eastern Time Barclays Global Healthcare Conference Date: Wednesday, March 10th at 10:55 a.m. Eastern Time For presentations
   Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast  2021/02/17 21:15:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サンガモ・セラピュ―ティクス SGMO Sangamo Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)